Biotechnology company Geron Corp. said Tuesday its developing cancer treatment GRNVAC1 met safety and tolerability goals in a midstage study.
Geron cancer drug meets midstage study goalsCourtesy Newsvine - business Tue, 12/08/2009 - 17:06
Biotechnology company Geron Corp. said Tuesday its developing cancer treatment GRNVAC1 met safety and tolerability goals in a midstage study. Related itemsBristol-Myers: Liver cancer drug failed in study
Retiring Amgen CEO Kevin Sharer to Hand Role to...
Erlotinib effective and with fewer side-effects after...
Samsung SCX-4200 3-in-1 True Multifunction Printer
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
|
Popular by tags WeekMonth |
Post new comment